ACS Global, Inc. (AMCY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ACS Global, Inc. (AMCY) trades at $3.00 with AI Score 46/100 (Grade C). ACS Global, Inc. specializes in the collection, processing, and long-term private storage of stem cells for potential future therapeutic applications. Market cap: $171.27M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for AMCY: AMCY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMCY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMCY: the 1 perspectives are evenly split.
How is this calculated? →ACS Global, Inc. (AMCY) Healthcare & Pipeline Overview
ACS Global, Inc. specializes in the collection, processing, and long-term private storage of stem cells, offering individuals a crucial service for potential future therapeutic applications. Operating within the evolving healthcare sector of medical diagnostics and research, the company positions itself to support advancements in cell therapy and regenerative medicine.
What Is the Investment Thesis for AMCY?
ACS Global, Inc. (AMCY) operates in the high-potential medical diagnostics and research sector, specifically focusing on the collection, processing, and long-term storage of stem cells for future therapeutic applications. With a market capitalization of $171.27M, the company is positioned to capitalize on the increasing global demand for specialized services within the burgeoning field of regenerative medicine and personalized cell therapy. A key value driver is the long-term nature of stem cell storage, potentially generating recurring revenue streams from preservation fees. The ongoing advancements in stem cell research, leading to new therapeutic applications, serve as a significant growth catalyst, expanding the addressable market for ACS Global's services. As more conditions become treatable with cell-based therapies, the perceived value and necessity of private stem cell banking are likely to increase. However, the company's listing on the OTC Other tier presents notable risk factors, including higher volatility, less stringent reporting requirements, and potentially lower liquidity, which necessitate thorough due diligence from institutional investors. The lack of publicly available detailed business model information also adds to the investment complexity.
Based on FMP financials and quantitative analysis
AMCY Key Highlights
- Market capitalization stands at $0.17 billion, indicating a micro-cap valuation within the healthcare sector.
- Specializes in the collection, processing, and long-term storage of stem cells for potential future therapeutic use.
- Operates within the Medical - Diagnostics & Research industry, a segment experiencing increasing demand for specialized services.
- Trades on the OTC Other tier, which implies specific considerations regarding market liquidity and disclosure standards.
- Positions itself to benefit from the growing field of regenerative medicine and personalized cell therapy.
Who Are AMCY's Competitors?
AMCY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMCY's Key Strengths?
- Specialized focus on stem cell collection, processing, and long-term storage.
- Operates in a growing market segment driven by advancements in regenerative medicine.
- Offers a personalized health service with long-term potential value for clients.
What Are AMCY's Weaknesses?
- Trades on the OTC Other tier, implying higher volatility and less stringent reporting.
- Limited public information regarding specific business segments and financial performance.
- Small market capitalization ($0.17 billion) may limit access to capital for expansion.
What Could Drive AMCY Stock Higher?
- Increasing global demand for specialized stem cell collection and storage services, driven by advancements in regenerative medicine.
- Potential for new therapeutic applications of stem cells to gain regulatory approval, expanding the perceived value of banked cells.
- Any future public disclosures or financial filings that provide greater transparency into the company's operations and performance.
- Growing public awareness and acceptance of personalized medicine, including private stem cell preservation, as a proactive health strategy.
What Are the Key Risks for AMCY?
- Operating on the OTC Other tier, which is associated with higher stock price volatility and less stringent reporting requirements.
- Lack of publicly available detailed business model and financial segments, hindering comprehensive investor analysis.
- Evolving and complex regulatory landscape for stem cell therapies and banking, which could impact operational compliance and market access.
- Intense competition from larger, better-funded companies in the broader biotechnology and healthcare sectors.
- Challenges in securing additional capital for growth or operational needs given its small market capitalization and OTC listing.
What Are the Growth Opportunities for AMCY?
- **Expanding Therapeutic Applications of Stem Cells:** The field of regenerative medicine is continually discovering new therapeutic applications for stem cells, ranging from treating neurodegenerative diseases and cardiovascular conditions to repairing damaged tissues and organs. As clinical trials progress and more stem cell-based therapies receive regulatory approval, the perceived value and utility of privately stored stem cells will significantly increase. This expansion broadens the addressable market for ACS Global, Inc.'s storage services, as more individuals become aware of the potential for their banked cells to treat a wider array of future health challenges. The timeline for this opportunity is ongoing, with continuous scientific breakthroughs expected over the next decade.
- **Increasing Public Awareness and Adoption of Personalized Medicine:** There is a growing global trend towards personalized medicine, where treatments are tailored to an individual's genetic makeup and biological profile. Stem cell banking aligns perfectly with this paradigm, offering a personalized biological resource. As public awareness campaigns and medical education emphasize the benefits of proactive health management and individualized treatments, the demand for services like those offered by ACS Global, Inc. is expected to rise. This shift in healthcare philosophy encourages individuals to invest in long-term health solutions, creating a sustained demand for stem cell preservation services over the next 5-10 years.
- **Technological Advancements in Stem Cell Processing and Storage:** Continuous innovation in cryopreservation techniques, cell viability assessment, and processing automation can enhance the efficiency, safety, and cost-effectiveness of stem cell banking. ACS Global, Inc. stands to benefit from adopting or developing advanced technologies that improve the quality and long-term integrity of stored cells, potentially attracting more clients and strengthening its competitive position. Improvements in these areas can also reduce operational costs and expand the types of cells that can be effectively stored. This opportunity is ongoing, driven by research and development within the biotech and cryogenics industries.
- **Strategic Partnerships and Geographic Expansion:** Collaborating with healthcare providers, fertility clinics, or research institutions could significantly expand ACS Global, Inc.'s client base and market reach. Partnerships could involve referral programs, co-marketing initiatives, or even joint ventures to establish new collection centers. Furthermore, exploring opportunities for geographic expansion, either domestically or internationally, into markets with high growth potential for stem cell therapies could unlock substantial new revenue streams. Such strategic moves would allow the company to tap into larger populations and diversify its client portfolio, with potential impacts visible within the next 3-7 years.
- **Development of Complementary Services:** Beyond core collection and storage, ACS Global, Inc. could explore offering complementary services that leverage its expertise and infrastructure. This might include genetic testing related to stem cell compatibility, consulting services for potential therapeutic applications, or even facilitating access to clinical trials for clients with banked cells. Diversifying the service portfolio could create additional revenue streams and enhance client loyalty by providing a more comprehensive solution for stem cell management. This opportunity could be explored and implemented over the next 2-5 years, building upon the existing client relationships and scientific foundation.
What Opportunities Does AMCY Have?
- Expanding therapeutic applications for stem cells in various medical conditions.
- Increasing public awareness and adoption of personalized medicine and proactive health.
- Technological advancements improving stem cell processing, viability, and storage methods.
- Potential for strategic partnerships or geographic expansion to broaden market reach.
What Threats Does AMCY Face?
- Evolving and complex regulatory landscape for stem cell therapies and banking.
- Intense competition from larger, more established players in the biotech and healthcare sectors.
- Risk of technological obsolescence if new, superior methods of cell preservation emerge.
- Dependence on the successful development and approval of future stem cell therapies.
What Are AMCY's Competitive Advantages?
- Specialized infrastructure and expertise in cryopreservation and cell processing.
- Adherence to stringent regulatory and quality control standards in a sensitive medical field.
- Long-term client relationships established through ongoing storage agreements.
- Proprietary laboratory protocols and scientific knowledge for stem cell viability.
What Does AMCY Do?
ACS Global, Inc., headquartered in Red Bank, New Jersey, operates within the specialized and forward-looking segment of medical diagnostics and research, focusing on stem cell services. The company's core business revolves around the meticulous collection, advanced processing, and secure, long-term cryopreservation of stem cells. These services are designed to enable individuals to privately bank their own stem cells, creating a personal biological resource for potential future use in cell therapy and regenerative medicine. The company was originally established as American CryoStem Corp., reflecting its foundational focus on cryopreservation technologies. In June 2011, the company underwent a strategic rebranding, changing its name to ACS Global, Inc. This name change likely signaled an intent for broader market reach or an expanded scope of services beyond its initial cryopreservation emphasis, aligning with the global advancements in stem cell research and applications. ACS Global's offerings cater to a growing demand from individuals and families who recognize the potential therapeutic value of stem cells in treating various diseases and conditions. By providing a secure and compliant infrastructure for stem cell storage, the company positions itself as a critical enabler in the personalized medicine landscape. The process typically involves collecting stem cells from sources like adipose tissue or umbilical cord blood, followed by sophisticated laboratory procedures to isolate, purify, and prepare the cells for cryopreservation. The long-term storage ensures the viability and integrity of these cells, making them accessible if and when future medical treatments require them. This specialized service requires adherence to stringent regulatory standards and advanced scientific protocols, placing ACS Global, Inc. at the intersection of biotechnology, healthcare services, and long-term biological asset management. The company's operational model is built around providing a highly technical and ethically sensitive service, aiming to empower individuals with options for their future health.
What Products and Services Does AMCY Offer?
- Collects stem cells from individuals for private preservation.
- Processes collected stem cells using specialized laboratory techniques.
- Ensures the isolation and purification of viable stem cells.
- Provides secure, long-term cryopreservation (freezing) of stem cells.
- Offers services for individuals to privately store their stem cells.
- Aims to make stem cells available for potential future use in cell therapy.
- Operates within the medical diagnostics and research sector.
How Does AMCY Make Money?
- Generates revenue through fees for initial stem cell collection and processing services.
- Secures recurring income from annual or periodic fees for long-term cryopreservation storage.
- Potentially charges for retrieval and preparation of stored cells for therapeutic use.
What Industry Does AMCY Operate In?
ACS Global, Inc. operates within the dynamic and rapidly evolving Medical - Diagnostics & Research industry, specifically targeting the niche of stem cell banking. This sector is characterized by significant scientific innovation and increasing investment in regenerative medicine. The global stem cell banking market is projected to grow substantially, driven by rising awareness of stem cell therapies, increasing prevalence of chronic diseases, and advancements in cell preservation technologies. ACS Global's business model of private stem cell preservation positions it within the direct-to-consumer segment of this market, catering to individuals seeking to secure biological assets for potential future medical needs. The competitive landscape includes both larger, established cord blood banks and smaller, specialized adipose-derived stem cell banks. While specific market share data for ACS Global is not available, its focus on private storage within the broader stem cell ecosystem places it amidst a growing, yet highly regulated and technically demanding, industry. The company's success is intrinsically linked to the continued progress and regulatory acceptance of cell-based therapies.
Who Are AMCY's Key Customers?
- Individuals and families interested in proactive health management.
- Parents seeking to preserve umbilical cord blood stem cells for their children.
- Adults looking to bank their own adipose-derived or other stem cells.
- Clients anticipating future medical needs or seeking options for regenerative therapies.
Company Profile
ACS Global, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Red Bank, US. The company is led by CEO Anthony Francis Dudzinski Jr.. AMCY has traded publicly since 2021.
ACS Global, Inc. (AMCY) Valuation Context
Relative to its peer group, AMCY's quantitative score of 46/100 is below the peer average of 64/100.
AMCY Financials
Bull Case vs Bear Case
Bull Case
- Specialized focus on stem cell collection, processing, and long-term storage.
- Operates in a growing market segment driven by advancements in regenerative medicine.
- Offers a personalized health service with long-term potential value for clients.
- Ongoing: Increasing global demand for specialized stem cell collection and storage services, driven by advancements in regenerative medicine.
Bear Case
- Trades on the OTC Other tier, implying higher volatility and less stringent reporting.
- Limited public information regarding specific business segments and financial performance.
- Small market capitalization ($0.17 billion) may limit access to capital for expansion.
- Ongoing: Operating on the OTC Other tier, which is associated with higher stock price volatility and less stringent reporting requirements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AMCY Latest News
No recent news available for AMCY.
AMCY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMCY.
Price Targets
Wall Street price target analysis for AMCY.
AMCY MoonshotScore
What does this score mean?
The MoonshotScore rates AMCY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anthony Francis Dudzinski Jr.
Unknown
Unknown. No specific background information, career history, education, or previous roles for Anthony Francis Dudzinski Jr. were provided in the source data.
Track Record: Unknown. No specific achievements, strategic decisions, or company milestones under the leadership of Anthony Francis Dudzinski Jr. were provided in the source data.
AMCY OTC Market Information
The "OTC Other" tier, also known as the Pink Sheets, represents the lowest and most speculative tier of the over-the-counter market. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements concerning financial health, minimum share price, and corporate governance, companies on the OTC Other tier face significantly fewer regulatory hurdles. This tier typically includes companies that do not meet the disclosure standards of higher OTC tiers (like OTCQX or OTCQB) or major exchanges, often providing little to no public information. This environment can lead to increased risk for investors due to a lack of transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- High price volatility due to low trading volume and speculative nature.
- Limited public information and financial transparency, making informed investment decisions difficult.
- Increased susceptibility to market manipulation due to less regulatory oversight.
- Difficulty in accurately valuing the company without comprehensive financial disclosures.
- Potential for delisting or further restrictions if disclosure standards are not met.
- Verify any available company filings, even if unofficial or limited.
- Research management's background, even if not publicly disclosed in detail.
- Thoroughly understand the company's business model and revenue generation.
- Assess the competitive landscape and market position within its niche.
- Monitor news and press releases for any operational updates or financial announcements.
- Evaluate the company's capital structure and potential need for future financing.
- Consider the overall regulatory environment for stem cell services.
- An established business description involving specific services (stem cell banking).
- A stated headquarters location (Red Bank, New Jersey).
- A market capitalization of $171.27M, indicating some level of market activity and valuation.
- A clear, albeit general, service offering for private stem cell preservation.
- The company's existence since at least 2011 under its current name suggests operational longevity.
AMCY Healthcare Stock FAQ
What services does ACS Global, Inc. provide in the stem cell market?
ACS Global, Inc. specializes in the comprehensive management of stem cells for private individuals. Its core services encompass the meticulous collection of stem cells, often from sources like adipose tissue, followed by advanced laboratory processing to isolate and prepare these cells. The company then provides secure, long-term cryopreservation, or freezing, of these stem cells. This service allows individuals to privately bank their own stem cells, creating a personal biological resource that can be potentially utilized for future therapeutic applications in regenerative medicine. The company positions itself as a critical service provider in the personalized medicine landscape, offering a proactive health solution for potential future medical needs.
How does ACS Global, Inc. navigate the regulatory landscape for stem cell banking and therapy?
While specific details of ACS Global, Inc.'s regulatory navigation are not publicly available, companies operating in the stem cell banking and therapy sector are subject to stringent oversight by health authorities such as the FDA in the United States. This includes regulations concerning the collection, processing, storage, and eventual therapeutic use of human cells, tissues, and cellular and tissue-based products (HCT/Ps). Compliance with Good Manufacturing Practices (GMP) and Good Tissue Practices (GTP) is typically crucial to ensure product safety and efficacy. The evolving nature of stem cell science means regulatory frameworks are also continually adapting, requiring companies like ACS Global to maintain vigilance and adapt their protocols to ensure ongoing compliance and ethical operation within this sensitive medical field.
What are the implications of ACS Global, Inc.'s OTC Other listing for investors?
ACS Global, Inc.'s listing on the OTC Other tier carries several significant implications for investors. This tier is known for its less stringent disclosure requirements compared to major exchanges like the NYSE or NASDAQ, meaning there is often limited public information available regarding the company's financials, operations, and governance. This lack of transparency can make it challenging for investors to conduct thorough due diligence and accurately assess the company's intrinsic value and risk profile. Furthermore, stocks on the OTC Other tier typically experience lower trading volumes and wider bid-ask spreads, leading to reduced liquidity. This can make it difficult for investors to buy or sell shares efficiently without impacting the price, potentially resulting in higher transaction costs and increased price volatility.
What are the key factors to evaluate for AMCY?
ACS Global, Inc. (AMCY) holds an AI score of 46/100 (low). Not financial advice.
How frequently does AMCY data refresh on this page?
AMCY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AMCY's recent stock price performance?
ACS Global, Inc. (AMCY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on stem cell collection, processing, and long-term storage. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AMCY overvalued or undervalued right now?
Valuing ACS Global, Inc. (AMCY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AMCY?
Before investing in ACS Global, Inc. (AMCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO background, track record, and specific financial performance is limited due to the company's OTC Other listing and lack of detailed public disclosures.
- Competitor information is generalized due to the absence of specific FMP PEER TICKERS in the provided source data.